SM
IKT icon

Sabby Management’s Inhibikase Therapeutics IKT Stock Holding History

Sabby Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,500
Closed -$147K – 136
2022
Q1 		$147K Sell
16,500
-54,336
-77% -$437K 0.02% 106
2021
Q4 		$625K Hold
70,836
– – 0.09% 98
2021
Q3 		$808K Buy
70,836
+636
+0.9% +$8.6K 0.11% 97
2021
Q2 		$1.18M Buy
+70,200
New +$2.07M 0.17% 76

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

Sabby Management's IKT Position: Q2 2022 in Review

Sabby Management sold out of Inhibikase Therapeutics (IKT) in Q2 2022, closing a stake of 16,500 shares — an estimated $147K sold.

Sabby Management first reported a position in IKT in Q2 2021 and held it in 4 quarters. The position peaked at $1.18M in Q2 2021. 22 funds tracked by Wall St. Rank hold IKT as of Q2 2022.

  • Sabby Management reported no remaining Inhibikase Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sabby Management sold 16,500 Inhibikase Therapeutics shares in Q2 2022, an estimated $147K.
  • Sabby Management first reported a position in Inhibikase Therapeutics in Q2 2021 and held it in 4 quarters.
  • Sabby Management's Inhibikase Therapeutics position peaked at $1.18M in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2022.

Based on Sabby Management's 13F filing for Q2 2022, filed 15 Aug 2022.